Considerations in the long-term management of asthma in ambulatory patients

American Journal of Health-System Pharmacy

Volumn 63, Issue SUPPL. 3, 2006, Pages

  Williams, Dennis M ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Ambulatory care; Antibodies; Asthma; Combined therapy; Omalizumab; Patient information; Steroids, cortico ; Sympathomimetic agents

Indexed keywords

BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CHLOROFLUOROCARBON; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; CROMOGLYCATE DISODIUM; FLUTICASONE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; FORMOTEROL FUMARATE; IPRATROPIUM BROMIDE; LEVALBUTEROL; MONTELUKAST; NEDOCROMIL; NITRIC OXIDE; OMALIZUMAB; PLACEBO; SALBUTAMOL; SALMETEROL; SALMETEROL XINAFOATE; THEOPHYLLINE DERIVATIVE; TRIAMCINOLONE ACETONIDE; ZAFIRLUKAST; ZILEUTON;

AMBULATORY CARE; ASTHMA; BONE METABOLISM; CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; COST EFFECTIVENESS ANALYSIS; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GROWTH RETARDATION; HUMAN; LONG TERM CARE; LUNG FUNCTION; METERED DOSE INHALER; PATIENT EDUCATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; SELF CARE; TREATMENT FAILURE; TREATMENT PLANNING;

EID: 33646817697     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp060128     Document Type: Review

References (33)

1. National Heart, Lung, and Blood Institute. Guidelines for the Diagnosis and Management of Asthma: Expert Panel Report 2. Washington, DC: U.S. Department of Health and Human Services; 1997. NIH publication no. 97-4051.
2. National Asthma Education and Prevention Program. Expert panel report: guidelines for the diagnosis and management of asthma update on selected topics-2002. J Allergy Clin Immunol. 2002; 110(5 suppl):141-219. www.nhlbi.nih.gov/guidelines/asthma/asthmafullrpt.pdf (accessed 2006 March 31).
3. Bateman ED. Measuring asthma control. Curr Opin Allergy Clin Immunol. 2001; 1:211-6.
4. Vollmer WM. Assessment of asthma control and severity. Ann Allergy Asthma Immunol. 2004; 93:409-13.
5. Use of ozone-depleting substances in foods, drugs, devices, or cosmetics. 21 CFR 2.125. http://frwebgate.access. gpo.gov/cgi-bin/get-cfr.cgi (accessed 2006 Feb 7).
6. Long-term effects of budesonide or nedocromil in children with asthma. The Childhood Asthma Management Program Research Group. N Engl J Med. 2000; 343:1054-63.
7. Busse W, Raphael GD, Galant S et al. Low-dose fluticasone propionate compared with montelukast for first-line treatment of persistent asthma: a randomized clinical trial. J Allergy Clin Immunol. 2001; 107:461-8.
8. Suissa S, Ernst P, Benayoun S et al. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med. 2000; 343:332-6.
9. McEvoy GK, ed. Corticosteroids general statement. In: AHFS Drug Information 2006. Bethesda, MD: American Society of Health-System Pharmacists; 2006:2974-87.
10. Kelly HW, Strunk RC, Donithan M et al. Growth and bone density in children with mild-moderate asthma: a cross-sectional study in children entering the Childhood Asthma Management Program (CAMP). J Pediatr. 2003; 142:286-91.
11. Agertoft L, Pedersen S. Effect of long-term treatment with inhaled budesonide on adult height in children with asthma. N Engl J Med. 2000; 343:1064-9.
12. Boushey HA, Sorkness CA, King TS et al. Daily versus as-needed corticosteroids for mild persistent asthma. N Engl J Med. 2005; 352:1519-28.
13. Greening AP, Ind PW, Northfield M et al. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group. Lancet. 1994; 344:219-24.
14. Evans DJ, Taylor DA, Zetterstrom O et al. A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma. N Engl J Med. 1997; 337:1412-8.
15. Nelson HS, Busse WW, Kerwin E et al. Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast. J Allergy Clin Immunol. 2000; 106:1088-95.
16. Masoli M, Holt S, Weatherall M et al. Dose-response relationship of inhaled budesonide in adult asthma: a meta-analysis. Eur Respir J. 2004; 23:552-8.
17. Pauwels RA, Lofdahl CG, Postma DS et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med. 1997; 337:1405-11.
18. Lemanske RF Jr, Sorkness CA, Mauger EA et al. Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol: a randomized controlled trial. JAMA. 2001; 285:2594-603.
19. Suissa S, Ernst P, Boivin JF et al. A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists. Am J Respir Crit Care Med. 1994; 149(3 pt 1):604-10.
20. Castle W, Fuller R, Hall J et al. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. Br Med J. 1993; 306:1034-7.
21. Nelson HS, Weiss ST, Bleecker ER et al. The salmeterol multicenter asthma research trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus sameterol. Chest. 2006; 129:15-26.
22. Knobil K, Yancey S, Kral K et al. Salmeterol multi-center asthma research trial (SMART): results from an interim analysis (abstract). Chest. 2003; 124:335.
23. Serevent Diskus package insert. Research Triangle Park, NC: GlaxoSmithKline; September 2004.
24. Advair Diskus package insert. Research Triangle Park, NC: GlaxoSmithKline; September 2004.
25. Mann M, Chowdhury B, Sullivan E et al. Serious asthma exacerbations in asthmatics treated with high-dose formoterol. Chest. 2003; 124:70-4.
26. Sin DD, Man J, Sharpe H et al. Pharmacological management to reduce exacerbations in adults with asthma: a systematic review and meta-analysis. JAMA. 2004; 292:367-76.
27. FDA Public Health Advisory: Serevent Diskus (salmeterol xinafoate inhalation powder), Advair Diskus (fluticasone propionate & salmeterol inhalation powder), Foradil Aerolizer (formoterol fumarate inhalation powder). November 18, 2005. www.fda.gov/cder/drug/advisory/LABA.htm (accessed 2006 Jan 31).
28. 2-adrenergic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med. 2000; 162:75-80.
29. Israel E, Chinchilli VM, Ford JG et al. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet. 2004; 364:1505-12.
30. Sullivan SD, Meltzer EO. Emerging therapeutic strategies for asthma management. J Manag Care Pharm. 2003; 9(5 suppl):14-21.
31. Xolair package insert. South San Francisco, CA: Genentech, Inc. March 2005.
32. Humbert M, Beasley R, Ayres J et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy. 2005; 60:309-16.
33. Oba Y, Salzman GA. Cost-effectiveness analysis of omalizumab in adults and adolescents with moderate-to-severe allergic asthma. J Allergy Clin Immunol. 2004; 114:265-9.